Vaxil Bio Ltd V.VXL

Update From Conclusion of COVID-19 Vaccine Study

[GajjarDr]

SOUND GOOD !!! MORE NEWS TO COME Y PANIC 

NESS-ZIONA, ISRAEL, Feb. 17, 2021 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, today reports results of the previously disclosed COVID-19 vaccine candidate challenge experiment and the strategy going forward. Vaxil established the USAMRIID collaboration (CRADA) based on the global need for a viable COVID-19 vaccine utilizing an alternative technology that demonstrates cellular and humoral responses, both of which are necessary. In this rapidly moving pandemic, variants have become the established infection model, which can be better addressed with Vaxil’s SP approach. Neutralizing antibody technologies may require frequent modifications while Vaxil’s signal peptide (“SP”) technology may provide long-term efficacy as the virus mutates. The USAMRIID COVID-19 mouse model challenge experiment demonstrated that Vaxil’s SP-based vaccine candidate generated a specific immune response. This was not, however, accompanied by vaccine protection of the animals. The Company plans to conduct additional analyses and on the basis of the understanding obtained, refine aspects of experiment design, including dosing levels and regimens, and alternate animal models that may allow future investigation of the unique and specific aspects of SP’s as immunogens. In addition, the Company will evaluate alternate peptide delivery approaches, including oral administration. This strategy focuses future efforts on the unique benefits of SP’s to sustain Vaxil’s competitive advantage over the longer term, beyond the current crisis environment, when it can realistically achieve approval for human use. The Company’s strategy to deliver value over the long-term is based on potentially unique benefits of SPs including their broad and strong immune response, both cellular and humoral, their reduced propensity to genetic mutation and the advantage of efficient manufacturing. “We were pleased to see the encouraging immune response and are excited to pursue further testing to highlight the unique advantages of SPs as a technology, though we had hoped to be able to demonstrate higher levels of protection in our first challenge experiment. It’s not uncommon to see such results at this early stage. We will work diligently with our international team of experts to further understand the data as COVID-19 is unfortunately going to be around for a long time. Whilst we had hoped to get into the clinic sooner, we believe that our technology could still be very relevant in the fight against COVID-19 and other infectious diseases,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, and continued, “thanks to our relatively strong balance sheet, we have sufficient funds to continue the pre-clinical development of our potential vaccine and our other research programs.” Dr. Michael Berelowitz, Vaxil’s newly appointed senior advisor the board of directors added: “Vaxil’s innovative approach in targeting the SP domain of clinically meaningful cancer and infectious disease molecules provided the stimulus for joining the company. The demonstration in this study of COVID-19 SP immunogenicity provides support and impetus for the concept. These results, together with those previously seen in multiple myeloma and tuberculosis, provide support for the Vaxil strategy moving forward and their investigative approach toward developing critical new therapeutics.”

[PowerofNow]

Clearly, todays news being extra vauge was made to drop the share price temporarily. think these masterminds know how the market will react? Points to a greater truth

[Maxmoe]

Ever notice or wonder why so many news releases , at the very top, and usually in bold print say  Not for distribution by US newswire or in United States it's because pumpers in the USA go to jail. 

[CamaroZL1]

Immune response was seen sounds like they need to adjust the dose. Sticking around, long term monthly trend is up

[PowerofNow]

Exactly, the news release clearly states as well, " In this rapidly moving pandemic, variants have become the established infection model, which can be better addressed with Vaxils SP approach. Neutralizing antibody technologies may require frequent modifications, while Vaxils signal peptide technology may provide long-term efficacy as the virus mutates.

[PowerofNow]

Absolutley dirty in a good Goren way... Dead Cat bouce is gonna be PHAT. WOOOOOW just look at that

[theticket]

Should make its way back below .10. The mcap was over 56M with 3 mil in the bank? Was all hype.

[PowerofNow]

The Prophet, theticket all your code names are easy to spot its the way you word urself

[theticket]

Code names?? The master detective. Hasnt solved a case to date.

[CamaroZL1]

Unless the cat becomes a bull at that point. The cancer treatment is still in cards the focus today is the dead mice focus away. Had they got the dose right this time and i sold i wouldn't have forgiven myself. I can live with this down 2 cents at the moment

[CamaroZL1]

Retrace targets are 30 36 and 44. Maxmoe i can still sell there with nice profit. This is not going straight to 10 or 8 cents.

[oceaneleven]

this reminds me of the day I watched my EDT tank from 1.82 to .28 ...it still has yet to recover..I think it's trading around 75 cents now...Good luck here with this paper.............

[LionWhisperer]

This post has been removed in accordance with Community Policy

[oceaneleven]

Is that you Specy???

[birch1]

You are probably right, but I took the 3 bagger today on VXL and now will just watch and see next steps

[PowerofNow]

[trinimetal]

Its always MAY with David Goren. After a decade of research in cancer and TB nothing to offer the public. Corvax was all bull. Should have known better but don't worry you can bet your bottom dollar dilution is coming.

[trinimetal]

He couldn't get it right this time but has the audacity to say SP "MAY" provide long term efficacy for mutations? Look STFU David Goren. We aren't falling for your bull shiit this time.

[bligicka]

Somebody was buying today !!!!

[theticket]

Did this guy actutally write sounds good??? Lmao. Hope you're not a real doctor.

[Maxmoe]

He's stuck in stage one of the 5 stages of grief and loss. I'm at#2, vette is at #1 and #3 simultaneously maybe?  denial, anger, bargaining, depression, and acceptance.

[Maxmoe]

Sorry, Camaro, not vette. 

[CamaroZL1]

Well im down 2 cents below cost average at the moment. I should have sold at 70 cents max, im at the easy come easy go stage to be honest

[Maxmoe]

I'm seeing a lot of denial, anger, and a little bargaining. We'll all get there, at least we weren't the mice. the 5 stages of grief and loss.  denial, anger, bargaining, depression, and acceptance.

[CamaroZL1]

already had many of those things at the 50 cent level. The waterfall already happened the time to sell was 50 60 70s. Sell the bottom? Im still going to make a profit, this was a good lesson on taking profits wasnt it